2-戊基-4,5-二氢-1H-咪唑 | 699-21-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 中文名称: 2-戊基-4,5-二氢-1H-咪唑
• 英文名称: 2-pentyl-4,5-dihydro-1H-imidazol
• 英文别名: 2-pentyl-4,5-dihydro-1H-imidazole；2-Pentyl-4,5-dihydro-1H-imidazol；2-Pentyl-2-imidazoline；2-pentylimidazoline；2-Pentyl-Δ²-imidazolin；2-Pentyl-2-imidazolin；2-Imidazoline, 2-pentyl-；2-pentyl-4,5-dihydro-1H-imidazole
• CAS: 699-21-8
• 化学式: C₈H₁₆N₂
• mdl: MFCD01720860
• 分子量: 140.228
• InChiKey: RBRDDDOKFJWHNR-UHFFFAOYSA-N

物化性质

• 熔点：
  53-54.6 °C
• 沸点：
  150-157 °C(Press: 34 Torr)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-戊基-4,5-二氢-1H-咪唑 生成 1-decyl-2-pentyl-1H-imidazole
  参考文献：
  名称：

  Substituted imidazoles

  摘要：

  公开号：

  US02404299A1
• 作为产物：
  描述：

  正己酸乙酯 在 magnesium 作用下， 生成 2-戊基-4,5-二氢-1H-咪唑
  参考文献：
  名称：

  Some Alkyl-glyoxalidines¹

  摘要：

  DOI：

  10.1021/ja01315a030

文献信息

• Triamide-substituted heterobicyclic compounds
  申请人：Pfizer Inc.

  公开号：US20030187053A1

  公开（公告）日：2003-10-02

  The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1 wherein R 1 -R 8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

  本发明涉及三酰胺MTP/ApoB抑制剂，其化学公式为1，其中R1-R8如说明书所述，以及包含这些化合物的药物组合物及其用途，以及制备这些化合物的方法。本发明的化合物可用于治疗肥胖和脂质紊乱。
• BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Do Steven

  公开号：US20090247567A1

  公开（公告）日：2009-10-01

  Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Benzopyran和benzoxepin的化合物I和II的分子式，包括其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用分子式I和II的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• [EN] FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY<br/>[FR] DÉRIVÉS DE [1,2,4]THIADIAZINE FUSIONNÉS AGISSANT EN TANT QU'INHIBITEURS DE KAT DE LA FAMILLE DES MYST
  申请人：CTXT PTY LTD

  公开号：WO2019043139A1

  公开（公告）日：2019-03-07

  A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

  一种化合物的化学式（I）：抑制MYST家族中一个或多个KATs的活性，即TIP60、KAT6B、MOZ、HBO1和MOF。
• Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor
  申请人：Recordati S.A., Chemical and Pharmaceutical Company

  公开号：US20020183290A1

  公开（公告）日：2002-12-05

  Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for &agr; 1a - and &agr; 1d -adrenergic receptors compared to &agr; 1b -receptors. This selectivity profile suggests the use of these derivatives in the treatment of symptoms of the lower urinary tract, including those associated to benign prostatic hyperplasia, without the side effects associated with hypotensive activity.

  描述了具有肾上腺素拮抗活性的衍生物，特别是相对于α1b-受体具有较高选择性的α1a-和α1d-肾上腺素受体。这种选择性配置表明这些衍生物可用于治疗下尿路症状，包括与良性前列腺增生相关的症状，而不会出现与降压活性相关的副作用。